Experimental models of Parkinson's disease

Nature Reviews Neuroscience

Volumn 2, Issue 5, 2001, Pages 325-332

  Beal, M Flint ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; NERVE PROTEIN; NEUROTOXIN; SNCA PROTEIN, HUMAN; SYNUCLEIN;

ANIMAL; BRAIN; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; PARKINSONISM; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; TRANSGENIC ANIMAL;

ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; NERVE TISSUE PROTEINS; NEUROTOXINS; PARKINSONIAN DISORDERS; SYNUCLEINS;

EID: 0035344211     PISSN: 14710048     EISSN: None     Source Type: Journal    
DOI: 10.1038/35072550     Document Type: Review

References (105)

1. Lang, A. E. & Lozano, A. M. Parkinson's disease. First of two parts. N. Engl. J. Med. 339, 1044-1053 (1998).
2. Lang, A. E. & Lozano, A. M. Parkinson's disease. Second of two parts. N. Engl. J. Med. 339, 1130-1143 (1998).
3. Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L. & Richardson, R. J. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50, 1346-1350 (1998).
4. Seidler, A. et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 46, 1275-1284 (1996).
5. Sveinbjomsdottir, S. et al. Familial aggregation of Parkinson's disease in Iceland. N. Engl. J. Med. 343, 1765-1770 (2000). Provides strong evidence for genetic factors that might have partial penetrance in the pathogenesis of Parkinson's disease.
6. Polymeropoulos, M. H. et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997).
7. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608 (1998).
8. Ungerstedt, U. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol. Scand. 367, S49-S68 (1971).
9. Sauer, H. & Oertel, W. H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59, 401-415 (1994).
10. Menegon, A., Board, P. G., Blackburn, A. C., Mellick, G. D. & Le Couteur, D. G. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 352, 1344-1346 (1998).
11. Caparros-Lefebvre, D. & Elbaz, A. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group. Lancet 354, 281-286 (1999).
12. Betarbet, R. et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neurosci. 3, 1301-1306 (2000). Describes a novel model of Parkinson's disease using intravenous infusion of the insecticide rotenone in rats. This compound is a selective complex I Inhibitor of an electron transport chain, yet the damage is confined to the substantia nigra.
13. Ouary, S. et al. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies. Neuroscience 97, 521-530 (2000).
14. Beal, M. F. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 23, 294-300 (2000).
15. Feany, M. B. & Bender, W. W. A Drosophila model of Parkinson's disease. Nature 404, 394-298 (2000). The first Drosophila model of overexpression of both mutant and wild-type α-synuclein. Interestingly, there was a selective loss of dopamine neurons and neuronal inclusions that resembled Lewy bodies.
16. Abeliovich, A. et al. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252 (2000).
17. Masliah, E. et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269 (2000).
18. van der Putten, H. et al. Neuropathology in mice expressing human α-synuclein. J. Neurosci. 20, 6021-6029 (2000).
19. Bloem, B. R. et al. The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease. J. Neurol. Sci. 97, 273-293 (1990).
20. Bezard, E. et al. Absence of MFTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurol. 155, 268-273 (1999).
21. Takahashi, N. et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl Acad. Sci. USA 94, 9933-9943 (1997).
22. Tipton, K. F. & Singer, T. P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61, 1191-1206 (1993).
23. Chan, P., DeLanney, L. E., Irwin, I., Langston, J. W. & DiMonte, D. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J. Neurochem. 57, 348-351 (1991).
24. Klivenyi, P. et al. Manganese superoxide dismutase overexpression attenuates MPTP toxicity. Neurobiol. Dis. 5, 253-258 (1998).
25. Przedborski, S. et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12, 1658-1667 (1992).
26. Andreassen, O. A. et al. Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP. Exp. Neurol. 167, 189-195 (2001).
27. Klivenyi, P. et al. Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity. Neuroreport 11, 1265-1268 (2000).
28. Zhang, J., Graham, D. G., Montine, T. J. & Ho, Y. S. Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase. J. Neuropathol. Exp. Neurol. 59, 53-61 (2000).
29. Pennathur, S., Jackson-Lewis, V., Przedborski, S. & Heinecke, J. W. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o'-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J. Biol. Chem. 274, 34621-34628 (1999).
30. Schulz, J. B., Matthews, R. T., Muqit, M. M. K., Browne, S. E. & Beal, M. F. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64, 936-939 (1995).
31. Good, P. F., Hsu, A., Werner, P., Perl, D. P. & Olanow, C. W. Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 57, 338-339 (1998).
32. Hantraye, P. et al. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nature Med. 2, 1017-1021 (1996). The first paper to show that an inhibitor of neuronal nitric oxide synthase produces marked neuroprotective effects against the clinical biochemical and neuropathological effects of MPTP in primates.
33. Matthews, R. T., Yang, L. & Beal, M. F. S-methylthiocitrulline, a neuronal nitric oxide synthase inhibitor, protects against malonate and MPTP neurotoxicity. Exp. Neurol. 143, 282-286 (1997).
34. Przedborski, S. et al. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl Acad. Sci. USA 93, 4565-4571 (1996). Showed that mice deficient in neuronal nitric oxide synthase were partially resistant to MPTP neurotoxicity, consistent with a role of peroxynitrite.
35. Dehmer, T., Lindenau, J., Haid, S., Dichgans, J. & Schulz, J. B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 74, 2213-2216 (2000).
36. Liberatore, G. T. et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nature Med. 5, 1403-1409 (1999). Showed that in mice deficient in inducible nitric oxide synthase, dopamine cell bodies were protected from MPTP toxicity but the dopamine terminals were not spared.
37. + and ATP induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide. Brain Res. 809, 58-67 (1998).
38. Mandir, A. S. et al. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc. Natl Acad. Sci. USA 96, 5774-5779 (1999). Mice deficient in poly(ADP-ribose) polymerase are resistant to MPTP, implicating it in cell death. This enzyme is activated by oxidative damage to DNA.
39. 10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxiciry. Exp. Neurol. 132, 279-283 (1995).
40. Burns, R. S. et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl Acad. Sci. USA 80, 4546-4550 (1983).
41. Varastet, M., Riche, D., Maziere, M. & Hantraye, P. Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. Neuroscience 63, 47-56 (1994).
42. Forno, L. S., Langston, J. W., DeLanney, L. E., Irwin, I. & Ricaurte, G. A. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann. Neurol. 20, 449-455 (1986).
43. Forno, L. S., Langston, J. W., DeLanney, L. E. & Irwin, I. An electron microscopic study of MPTP-induced inclusion bodies in an old monkey. Brain Res. 448, 150-157 (1983).
44. Albanese, A. et al. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates. Neuroscience 55, 823-832 (1993).
45. Brownell, A. L. et al. Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease. Nature Med. 4, 1308-1312 (1998).
46. Hantraye, P. et al. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibers following chronic MPTP administration in baboons. Neuroscience 53, 169-178 (1993).
47. Bankiewicz, K. S. et al. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 39, 7-16 (1986).
48. Bergman, H., Wichmann, T. & DeLong, M. R. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249, 1436-1438 (1990).
49. Wichmann, T., Kliem, M. A. & DeLong, M. R. Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates. Exp. Neurol. 167, 410-424 (2001).
50. Tatton, N. A. & Kish, S. J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77, 1037-1048 (1997).
51. Hartmann, A. et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl Acad. Sci. USA 97, 2875-2880 (2000).
52. Tatton, N. A. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol. 166, 29-43 (2000).
53. Wullner, U. et al. Cell death and apoptosis regulating proteins in Parkinson's disease - a cautionary note. Acta Neuropathol. (Berl.) 97, 408-412 (1999).
54. Yang, L. et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J. Neurosci. 18, 8145-8152 (1998). First paper to show that an anti-apoptotic protein can protect against both acute and chronic MPTP toxicity.
55. Offen, D. et al. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Proc. Natl Acad. Sci. USA 95, 5789-5794. (1998).
56. Klivenyi, P. et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Med. 5, 347-350 (1999).
57. Vila, M. et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 98, 2837-2842 (2001).
58. Eberhardt, O. et al. Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 20, 9126-9134 (2000). Shows that an inhibitor of apoptosis preferentially protects dopamine cell bodies, whereas the growth factor GDNF protects dopamine terminals.
59. Trimmer, P. A., Smith, T. S., Jung, A. B. & Bennett, J. P., Jr Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration 5, 233-239 (1996).
60. Saporito, M. S., Brown, E. M., Miller, M. S. & Carswell, S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyt-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol. Exp. Ther. 288, 421-427 (1999).
61. Saporito, M. S., Thomas, B. A. & Scott, R. W. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J. Neurochem. 75, 1200-1208 (2000).
62. Waldmeier, P. C., Spooren, W. P. & Hengerer, B. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease. Naunyn Schmiedebergs Arch. Phamacol. 362, 526-537 (2000).
63. Langston, J. W. et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46, 598-605 (1999).
64. Kurkowska-Jastrzebska, I., Wronska, A., Kohutnicka, M., Czlonkowski, A. & Czlonkowska, A. The inflammatory reaction following 1-methyt-4-phenyf-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp. Neurol. 156, 50-61 (1999).
65. Teismann, P. & Ferger, B. Inhibition of the cyclcoxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39, 167-174 (2001).
66. Klivenyi, P. et al. Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity. J. Neurochem. 71, 2634-2637 (1998).
67. Ferger, B., Teismann, P., Earl, C. D., Kuschinsky, K. & Oertel, W. H. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Ach. Pharmacol. 360, 256-261 (1999).
68. Mohanakumar, K. P., Muralikrishnan, D. & Thomas, B. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Res. 864, 281-290 (2000).
69. Brouillet, E. & Beal, M. F. NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. Neuroreport 4, 387-390 (1993).
70. Lange, K. W. et al. The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates. Naunyn Schmiedebergs Arch. Pharmacol. 348, 586-592 (1993).
71. Zuddas, A. et al. MK-801 prevents 1-methyl-4-prienyl-1,2,3,6-tetrahydropyridinine-induced parkinsonism in primates. J. Neurochem. 59, 733-739 (1992).
72. Lau, Y. S. & Mouradian, M. M. Protection against acute MPTP-induced dopamine depletion in mice by adenosine A1 agonist. J. Neurochem. 60, 768-771 (1993).
73. Benazzouz, A. et al. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur. J. Pharmacol. 284, 299-307 (1995).
74. Boireau, A. et al. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. Neuroreport 5, 2657-2660 (1994).
75. Muralikrishnan, D. & Mohanakumar, K. P. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J. 12, 905-912 (1998).
76. Zou, L. et al. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci. Lett. 281, 167-170 (2000).
77. Moussaoui, S. et al. The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp. Neurol. 166, 235-245 (2000).
78. Matthews, R. T. et al. Novel free radical spin traps protect against malonate and MPTP neurotoxicity. Exp. Neurol. 157, 120-126 (1999).
79. Callier, S., Morissette, M., Grandbois, M. & Di Paolo, T. Stereospecific prevention by 17β-estradiol of MPTP-induced dopamine depletion in mice. Synapse 37, 245-251 (2000).
80. Gene, S. et al. Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production. Neurosci. Lett. 298, 139-141 (2001).
81. Costa, S., Iravani, M. M., Pearce, R. K. & Jenner, P. Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets. Eur. J. Pharmacol. 412, 45-50 (2001).
82. Gash, D. M. et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380, 252-255 (1996).
83. Tomac, A. et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373, 335-339 (1995). First paper to show that GDNF has restorative effects on dopamine neurons after MPTP treatment
84. Kordower, J. H. et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773 (2000). Showed that administration of GDNF using a lentiviral vector in primates was highly effective against MPTP toxicity.
85. Costantini, L. C. et al. A novel immunophilin ligand: distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease. Neurobiol. Dis. 5, 97-106 (1998).
86. Steiner, J. P. et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc. Natl Acad. Sci. USA 94, 2019-2024 (1997). References 85 and 86 show that Immunophilins produce restorative effects after MPTP treatment.
87. Bodis-Wollner, I. et al. Acetyt-levo-carnitine protects against MPTP-induced parkinsonism in primates. J. Neural. Transm. Park. Dis. Dement. Sect. 3, 63-72 (1991).
88. 10 attenuates the MPTP induced loss of striatai dopamine and dopaminergic axons in aged mice. Brain Res. 783, 109-114 (1997).
89. 10 is reduced in mitochondria from parkinsonian patients. Ann. Neurol. 42, 261-264 (1997).
90. Kowall, N. W. et al. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11, 211-213 (2000).
91. Gurney, M. E. et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772-1775 (1994).
92. Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506 (1996).
93. Hashimoto, M. et al. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10, 717-721 (1999).
94. Shimura, H. et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genet. 25, 302-305 (2000).
95. Vila, M. et al., α-synuclein upregulation in substantia nigra dopaminergic neurons following administration of the parkinsonan toxin MPTP. J. Neurochem. 74, 721-729 (2000).
96. Przedborski, S. et al. Oxidative post-translational modifications of α-cynuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Neurochem. 76, 637-640 (2001).
97. Giasson, B. I. et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985-989 (2000). Used antibodies to nitrated α-synuclein to show that the α-synuclein In Lewy bodies in Parkinson's disease is nitrated, consistent with oxidative damage mediated by peroxynitrite.
98. Hsu, L. J. et al. α-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157, 401-410 (2000).
99. Lee, M., Hyun, D. H., Halliwell, B. & Jenner, P. Effect of the overexpression of wild-type or mutant α-synuclein on cell susceptibility to insult. J. Neurochem. 76, 998-1009 (2001).
100. Bergman, H., Wichmann, T., Karmon, B. & DeLong, M. R. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol. 72, 507-520 (1994).
101. Filion, M., Tremblay, L. & Bedard, P. J. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res. 547, 152-161 (1991).
102. Wichmann, T. et al. Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates. Exp. Brain Res. 125, 397-409 (1999).
103. Bronstein, J. M., DeSalles, A. & DeLong, M. R. Stereotactic pallidotomy in the treatment of Parkinson disease: an expert opinion. Ach. Neurol. 56, 1064-1069 (1999).
104. Limousin, P. et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med. 339, 1105-1111 (1998).
105. Forno, L. S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55, 259-272 (1996).